1 week Ago By Defense World Staff
Legal & General Group Plc decreased its position in Arvinas, Inc. (NASDAQ:ARVN – Free Report) by 14.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC.
The institutional investor owned 53,610 shares of the company’s stock after selling 9,344 shares during the quarter. Legal & General Group Plc owned about 0.08% of Arvinas worth $1,028,000 as of its most recent filing with the SEC.
A number of other hedge funds have also recently added to or reduced their stakes in ARVN. Norges Bank bought a new stake in shares of Arvinas during the 4th quarter worth about $23,845,000. JPMorgan Chase & Co.
boosted its position in Arvinas by 18.7% during the third quarter. JPMorgan Chase & Co.
now owns 2,329,303 shares of the company’s stock worth $57,371,000 after purchasing an additional 367,343 shares during the period. BIT Capital GmbH grew its holdings in Arvinas by 291.7% during the fourth quarter.
BIT Capital GmbH now owns 263,527 shares of the company’s stock valued at $5,052,000 after purchasing an additional 196,246 shares during the last quarter. Finepoint Capital LP raised its position in shares of Arvinas by 24.3% in the fourth quarter.
Finepoint Capital LP now owns 713,778 shares of the company’s stock valued at $13,683,000 after purchasing an additional 139,400 shares during the period. Finally, Barclays PLC lifted its stake in shares of Arvinas by 198.9% in the third quarter.
Barclays PLC now owns 121,699 shares of the company’s stock worth $2,998,000 after buying an additional 80,984 shares during the last quarter. Institutional investors and hedge funds own 95.19% of the company’s stock.
Insider Activity at ArvinasIn other Arvinas news, insider Ian Taylor sold 9,020 shares of the business’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $16.71, for a total value of $150,724.
20. Following the transaction, the insider now owns 159,121 shares of the company’s stock, valued at approximately $2,658,911.91.
The trade was a 5.36 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Also, CEO John G. Houston sold 31,338 shares of Arvinas stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.
72, for a total value of $523,971.36. Following the completion of the transaction, the chief executive officer now directly owns 1,157,480 shares of the company’s stock, valued at $19,353,065.
60. This represents a 2.64 % decrease in their ownership of the stock.
The disclosure for this sale can be found here. Insiders sold 50,230 shares of company stock valued at $769,402 in the last ninety days. Insiders own 5.
23% of the company’s stock. Analyst Upgrades and DowngradesSeveral brokerages recently commented on ARVN. Morgan Stanley dropped their target price on shares of Arvinas from $48.
00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, March 13th. The Goldman Sachs Group cut their price objective on Arvinas from $15.
00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday, April 17th. Wedbush lowered Arvinas from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $57.
00 to $12.00 in a report on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and set a $81.
00 price target on shares of Arvinas in a report on Monday, April 7th. Finally, Oppenheimer downgraded shares of Arvinas from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 11th. Five investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company.
According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $34.33.View Our Latest Analysis on ARVNArvinas Trading Down 1.
0 %ARVN stock opened at $9.05 on Monday. The firm has a market cap of $622.
39 million, a P/E ratio of -3.27 and a beta of 2.30.
Arvinas, Inc. has a 1-year low of $5.94 and a 1-year high of $37.
38. The business’s 50 day moving average is $10.58 and its 200-day moving average is $17.
99. Arvinas (NASDAQ:ARVN – Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.
63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44.
Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%.
During the same quarter in the previous year, the firm earned ($2.53) earnings per share. Sell-side analysts forecast that Arvinas, Inc.
will post -3.81 EPS for the current year. About Arvinas (Free Report)Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.Further ReadingFive stocks we like better than Arvinas3 Small Caps With Big Return PotentialTexas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryWhat is the NASDAQ Stock Exchange?O’Reilly Automotive: An Anytime Buy for Buy-and-Hold InvestorsMastering Discipline: Overcoming Emotional Challenges In TradingChipotle Mexican Grill Serves Smoking Hot Entry Point in Q2.
